|
| Press Releases |
|
 |
|
| Friday, October 31, 2025 |
|
|
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus |
| HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). more info >> |
|
| Wednesday, September 17, 2025 |
|
|
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna. more info >> |
|
| Thursday, April 24, 2025 |
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. more info >> |
|
| Tuesday, April 15, 2025 |
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |
| HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |
|
| Friday, October 25, 2024 |
|
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California. more info >> |
|
| Wednesday, September 11, 2024 |
|
|
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain. more info >> |
|
| Friday, June 21, 2024 |
|
|
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. more info >> |
|
| Wednesday, June 5, 2024 |
|
|
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) |
| HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. more info >> |
|
| Wednesday, January 11, 2023 |
|
|
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) |
| HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
Nov 20, 2025 23:00 HKT/SGT
|
|
|
Doubleview Gold Corp. Highlights Scandium Potential at Hat Project, a Key Enabler for the Electrification Economy
Nov 20, 2025 22:09 HKT/SGT
|
|
|
PLN Reaffirms Commitment to Advancing a Just Energy Transition at COP30 
Nov 20, 2025 21:00 HKT/SGT
|
|
|
U.S. Polo Assn. Receives Multiple Global Honors Recognizing Excellence in Brand, Content, and Digital Growth
Nov 20, 2025 20:00 HKT/SGT
|
|
|
BIP Asia Forum and Entrepreneur Day set for December
Nov 20, 2025 18:29 HKT/SGT
|
|
|
WASH debuts on MAI, targeting 160 new branches for 2026-2027
Nov 20, 2025 17:00 HKT/SGT
|
|
|
Shoucheng Holdings Launches Robot Tech Experience Store Naming Event
Nov 20, 2025 16:10 HKT/SGT
|
|
|
EdgePoint Marks Five Years of Building ASEAN's Digital Connectivity, with 16,000th site milestone
Nov 20, 2025 12:28 HKT/SGT
|
|
|
Special Autumn Event: "Anime Tokyo Station Autumn Festival"
Nov 20, 2025 13:00 JST
|
|
|
Think Business, Think Hong Kong returns to Milan to deepen Hong Kong-Italy business ties
Nov 20, 2025 11:33 HKT/SGT
|
|
|
ANIME TOKYO STATION ON ROBLOX: New Game "ANIME SKILL TCG" Out Now!
Nov 20, 2025 11:00 JST
|
|
|
DENSO and DELPHY Sign Joint Development Agreement to Accelerate Data-Driven Smart Horticulture
Nov 19, 2025 23:41 JST
|
|
|
NEC Presents the Decarbonization Potential of its CropScope Agricultural Solution at COP30
Nov 19, 2025 23:15 JST
|
|
|
Fujitsu recognized as the only Japan-headquartered company to be an Emerging Leader in Gartner(R) Emerging Market Quadrant for Generative AI Engineering
Nov 19, 2025 22:40 JST
|
|
|
Doubleview Gold Corp. Closes Final Tranche of Non-Brokered Private Placement for Gross Proceeds of $7,181,400
Nov 19, 2025 19:09 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
